,19 Two pharmacological ezrin inhibitors have been better characterized in cancer models, NSC305787 and NSC668394, with NSC305787 being considered more potent and with a more favorable pharmacokinetic profile,6,7 which led us to choose this compound for the studies in vitro in models of cervical and gastric cancer. The gene discussed is EZR; the disease is gastric cancer.